Table 3.
The toxic effects of nivolumab in advanced melanoma
| Adverse events | Nivolumab + ipilimumab vs ipilimumab
|
Nivolumab vs dacarbazine
|
||
|---|---|---|---|---|
| Pooled RR and 95% CI | P-value | Pooled RR and 95% CI | P-value | |
| Grade 3 and 4 | ||||
| Diarrhea | 1.38 (0.85–2.26) | 0.19 | 0.70 (0.09–5.41) | 0.73 |
| Rash | 2.70 (1.11–6.57) | 0.03 | NA* | NA* |
| Pruritus | 4.27 (0.75–24.35) | 0.10 | 2.99 (0.12–73.71) | 0.50 |
| Fatigue | 4.51 (1.44–14.15) | 0.01 | 0.23 (0.05–1.01) | 0.05 |
| Vomiting | 5.41 (1.03–28.34) | 0.05 | 0.45 (0.08–2.46) | 0.36 |
| Nausea | 2.30 (0.65–8.15) | 0.20 | None^ | None^ |
| All grades | ||||
| Diarrhea | 1.32 (1.10–1.59) | 0.003 | 0.68 (0.31–1.50) | 0.35 |
| Rash | 1.28 (1.05–1.56) | 0.01 | NA* | NA* |
| Pruritus | 0.99 (0.81–1.21) | 0.93 | 4.96 (1.47–16.72) | 0.01 |
| Fatigue | 2.30 (0.33–15.83) | 0.40 | 5.69 (0.05–636.7) | 0.47 |
| Vomiting | 1.91 (1.25–2.92) | 0.003 | 0.27 (0.17–0.43) | 0.000 |
Notes: NA*: not provided; none^: there were no patients with nausea.
Abbreviations: RR, risk ratio; CI, confidence interval.